Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate ...

In the case of pertuzumab and trastuzumab, preclinical data suggest that synergism may result from the ability of pertuzumab, which binds to the dimerization arm of HER2 (domain II) to inhibit ...

Schematic illustration of ErbB receptor structures and dimerization patterns ... powerful approach to overcome resistance. By combining HER3-targeting antibodies with cytotoxic payloads, ADCs ...

HER3 functions through its interaction with other ErbB receptors, particularly HER2, forming potent signaling pairs that drive cell survival, proliferation, and metastasis. These dimerized ...

The FDA cleared an investigational new drug application for AVZO-1418/DB-1418, and a phase 1/2 trial in advanced solid tumors ...

Zenocutuzumab targets human epidermal growth factor receptor (HER)2 and HER3 and received accelerated approval in advanced NSCLC and pancreatic adenocarcinoma harboring neuregulin 1 gene fusions.

The HER2-targeted antibody-drug conjugate that Pfizer gained from its Seagen buyout has delivered positive results in a pivotal study among Chinese patients with newly diagnosed bladder cancer ...

The APHINITY study confirmed significant overall survival benefits of a Perjeta-based regimen in HER2-positive early-stage breast cancer, especially for lymph node-positive patients. Ten-year data ...

The Colorado-based biotech is currently evaluating ELVN-002, which is designed to inhibit the HER2 pathway in solid tumors, in a pair of phase 1 trials. One of these studies is looking at ELVN-002 ...